{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:15Z","timestamp":1759336515380,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071605233"},{"type":"electronic","value":"9781071605240"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0524-0_43","type":"book-chapter","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T17:04:25Z","timestamp":1595351065000},"page":"835-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting an Intrinsically Disordered Protein by Covalent Modification"],"prefix":"10.1007","author":[{"given":"Hung Huy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"\u00c1br\u00e1nyi-Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Vandenbussche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy Mikl\u00f3s","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tompa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"43_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0968-0004(02)02169-2","volume":"27","author":"P Tompa","year":"2002","unstructured":"Tompa P (2002) Intrinsically unstructured proteins. Trends Biochem Sci 27:527\u2013533","journal-title":"Trends Biochem Sci"},{"key":"43_CR2","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1021\/cr400525m","volume":"114","author":"R van der Lee","year":"2014","unstructured":"van der Lee R, Buljan M, Lang B et al (2014) Classification of intrinsically disordered regions and proteins. Chem Rev 114:6589\u20136631","journal-title":"Chem Rev"},{"key":"43_CR3","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1073\/pnas.1512799112","volume":"112","author":"M Arai","year":"2015","unstructured":"Arai M, Sugase K, Dyson HJ et al (2015) Conformational propensities of intrinsically disordered proteins influence the mechanism of binding and folding. Proc Natl Acad Sci U S A 112:9614\u20139619","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034687","volume":"7","author":"R Pancsa","year":"2012","unstructured":"Pancsa R, Tompa P (2012) Structural disorder in eukaryotes. PLoS One 7:e34687","journal-title":"PLoS One"},{"key":"43_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev.biophys.37.032807.125924","volume":"37","author":"VN Uversky","year":"2008","unstructured":"Uversky VN, Oldfield CJ, Dunker AK (2008) Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 37:215\u2013246","journal-title":"Annu Rev Biophys"},{"key":"43_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.tibtech.2006.07.005","volume":"24","author":"Y Cheng","year":"2006","unstructured":"Cheng Y, LeGall T, Oldfield CJ et al (2006) Rational drug design via intrinsically disordered protein. Trends Biotechnol 24:435\u2013442","journal-title":"Trends Biotechnol"},{"key":"43_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cbpa.2010.06.169","volume":"14","author":"SJ Metallo","year":"2010","unstructured":"Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 14:481\u2013488","journal-title":"Curr Opin Chem Biol"},{"key":"43_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844\u2013848","journal-title":"Science"},{"key":"43_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep15686","volume":"5","author":"LI Iconaru","year":"2015","unstructured":"Iconaru LI, Ban D, Bharatham K et al (2015) Discovery of small molecules that inhibit the disordered protein, p27(Kip1). Sci Rep 5:15686","journal-title":"Sci Rep"},{"key":"43_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan HV, Kong Y, Merchant M et al (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat Med 15:750\u2013756","journal-title":"Nat Med"},{"key":"43_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087133","volume":"9","author":"G Toth","year":"2014","unstructured":"Toth G, Gardai SJ, Zago W et al (2014) Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson\u2019s disease. PLoS One 9:e87133","journal-title":"PLoS One"},{"key":"43_CR12","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1172\/JCI66398","volume":"123","author":"JK Myung","year":"2013","unstructured":"Myung JK, Banuelos CA, Fernandez JG et al (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123:2948\u20132960","journal-title":"J Clin Invest"},{"key":"43_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd3410","volume":"10","author":"J Singh","year":"2011","unstructured":"Singh J, Petter RC, Baillie TA et al (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307\u2013317","journal-title":"Nat Rev Drug Discov"},{"key":"43_CR14","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1021\/bi050247e","volume":"44","author":"JG Robertson","year":"2005","unstructured":"Robertson JG (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44:5561\u20135571","journal-title":"Biochemistry"},{"key":"43_CR15","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.bmcl.2016.02.067","volume":"26","author":"H Cheng","year":"2016","unstructured":"Cheng H, Nair SK, Murray BW (2016) Recent progress on third generation covalent EGFR inhibitors. Bioorg Med Chem Lett 26:1861\u20131868","journal-title":"Bioorg Med Chem Lett"},{"key":"43_CR16","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1021\/acs.jmedchem.5b01082","volume":"58","author":"J Engel","year":"2015","unstructured":"Engel J, Richters A, Getlik M et al (2015) Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach. J Med Chem 58:6844\u20136863","journal-title":"J Med Chem"},{"key":"43_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1073\/pnas.1313733111","volume":"111","author":"P Schwartz","year":"2014","unstructured":"Schwartz P, Kuzmic P, Solowiej J et al (2014) Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci U S A 111:173\u2013178","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.bbapap.2011.08.005","volume":"1824","author":"Y Ono","year":"2012","unstructured":"Ono Y, Sorimachi H (2012) Calpains: an elaborate proteolytic system. Biochim Biophys Acta 1824:224\u2013236","journal-title":"Biochim Biophys Acta"},{"key":"43_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature07353","volume":"456","author":"T Moldoveanu","year":"2008","unstructured":"Moldoveanu T, Gehring K, Green DR (2008) Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature 456:404\u2013408","journal-title":"Nature"},{"key":"43_CR20","doi-asserted-by":"crossref","unstructured":"Gehringer M, Laufer SA (2019) Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem","DOI":"10.1021\/acs.jmedchem.8b01153"},{"key":"43_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","volume":"160","author":"P Abranyi-Balogh","year":"2018","unstructured":"Abranyi-Balogh P, Petri L, Imre T et al (2018) A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur J Med Chem 160:94\u2013107","journal-title":"Eur J Med Chem"},{"key":"43_CR22","unstructured":"Cravatt BF (2017) Compositions and methods of modulating immune response.\u00a0Patent WO2017210600A1. World Intellectual Property Organization (WIPO)"},{"key":"43_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00807643","volume":"1997","author":"U Beyer","year":"1997","unstructured":"Beyer U, Krueger M, Schumacher P et al (1997) Synthesis of new bifunctional maleimide compounds for the preparation of chemoimmunoconjugates. Chem Month 1997:91\u2013102","journal-title":"Chem Month"},{"key":"43_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pep.2018.01.002","volume":"145","author":"HH Nguyen","year":"2018","unstructured":"Nguyen HH, Volkov AN, Vandenbussche G et al (2018) In vivo biotinylated calpastatin improves the affinity purification of human m-calpain. Protein Expr Purif 145:77\u201384","journal-title":"Protein Expr Purif"},{"key":"43_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","volume":"24","author":"DA Shannon","year":"2015","unstructured":"Shannon DA, Weerapana E (2015) Covalent protein modification: the current landscape of residue-specific electrophiles. Curr Opin Chem Biol 24:18\u201326","journal-title":"Curr Opin Chem Biol"},{"key":"43_CR26","doi-asserted-by":"publisher","first-page":"10072","DOI":"10.1021\/jm501412a","volume":"57","author":"ME Flanagan","year":"2014","unstructured":"Flanagan ME, Abramite JA, Anderson DP et al (2014) Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem 57:10072\u201310079","journal-title":"J Med Chem"},{"key":"43_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ab.2003.12.018","volume":"327","author":"DJ Murphy","year":"2004","unstructured":"Murphy DJ (2004) Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. Anal Biochem 327:61\u201367","journal-title":"Anal Biochem"},{"key":"43_CR28","first-page":"1","volume":"46","author":"RA Copeland","year":"2005","unstructured":"Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46:1\u2013265","journal-title":"Methods Biochem Anal"},{"key":"43_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/abio.2000.4685","volume":"286","author":"P Kuzmic","year":"2000","unstructured":"Kuzmic P, Elrod KC, Cregar LM et al (2000) High-throughput screening of enzyme inhibitors: simultaneous determination of tight-binding inhibition constants and enzyme concentration. Anal Biochem 286:45\u201350","journal-title":"Anal Biochem"},{"key":"43_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-4939-9030-6_15","volume":"1929","author":"HH Nguyen","year":"2019","unstructured":"Nguyen HH, Tompa P, Pauwels K (2019) Calpain purification through calpastatin and calcium: strategy and procedures. Methods Mol Biol 1929:233\u2013244","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Intrinsically Disordered Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0524-0_43","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T21:10:43Z","timestamp":1645132243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-0524-0_43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071605233","9781071605240"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0524-0_43","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"22 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}